

CLAIMS

1. A pharmaceutical composition for influencing angiogenesis, comprising

(a) for positive regulation
one or more bodies of
CD66a, CD66a fragments or CD66a-derived glycostructures, or CD66a ligands,
ligand fragments or structures derived therefrom, as well as substances inducing the
expression of CD66a or CD66a ligand,

or

(b) for negative regulation
one or more bodies of
substances which inhibit the interaction between CD66a and CD66a ligands or
substances which inhibit the expression of CD66a or CD66a ligand.

2. The composition according to claim 1 (b), characterized in that the substances which inhibit
the interaction between CD66a and CD66a ligands are antibodies, proteins or peptides which
bind specifically to one or more functional domains of CD66a or its ligands.

3. The composition according to claim 2, characterized in that the antibody is an anti-CD66a
antibody.

4. The composition according to claim 3, characterized in that the antibody is the monoclonal
anti-CD66a 4D1/C2 antibody which was deposited with DSMZ (German-Type Collection of
Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22,
1998.

5. The composition according to claim 1 (b), characterized in that the substances which inhibit
the expression of CD66a or CD66a ligand are anti-sense oligonucleotides or anti-sense
RNA.

6. The composition according to any of claims 1 (b) to 5, characterized in that it is capable of stopping tumor angiogenesis of lung cancer, breast cancer and colon carcinoma.
7. The composition according to claim 1 (a), characterized in that the substances inducing the expression of CD66a or CD66a ligand are DNA coding for CD66a, CD66a isoforms or CD66a fragments.